Effective long-term inhibition of thromboxane production but not of serotonin release in patients with coronary heart disease by 30 mg/d acetylsalicylic acid dosage

• Published in: Prostaglandins, leukotrienes and essential fatty acids leukotrienes and essential fatty acids, 1998-07, Vol.59 (1), p.17-21
• Main Authors: GAJDOS, M, SPUSTOVA, V, SEBEKOVA, K, KRIVOSIKOVA, Z, DZURIK, R
• Format: Article
• Language: English
• Subjects: Aspirin - therapeutic use; Biological and medical sciences; Blood Coagulation - drug effects; Blood. Blood coagulation. Reticuloendothelial system; Coronary Disease - physiopathology; Dose-Response Relationship, Drug; Humans; Medical sciences; Myocardial Ischemia - prevention & control; Pharmacology. Drug treatments; Serotonin - secretion; Thromboxane A2 - antagonists & inhibitors; Thromboxane A2 - urine; Thromboxane B2 - metabolism
• ISSN: 0952-3278; 1532-2823
• DOI: 10.1016/S0952-3278(98)90047-3

Efficacy of aspirin (Acetylsalicylic acid, ASA) antiaggregatory prevention was demonstrated in a series of clinical trials. The recommended ASA doses decreased gradually and doses 50-30 mg ASA/d are intensively studied at the present time. A group of 42 patients with coronary heart disease was evaluated: (1) Basal TXB 2 production during spontaneous blood clotting was 360 ± 37.6 ng/ml; (2) Two initial doses were tested: while 200 mg ASA inhibited, during spontaneous blood clotting, median TXB 2 production by 99.9% (serum TXB 2 concentration 1.35 ng/ml), 30 mg ASA median inhibition was just 42.0% (serum TXB 2 151 ng/ml); (3) 30 mg ASA/d maintenance dose was evaluated for 3 months. The median TXB 2 production inhibition was 98.5% (serum TXB 2 3.75 ng/ml, first month) and 94.0% (serum TXB 2 14.2 ng/ml, third month); (4) Four patients did not respond sufficiently, because of noncompliance verified by the determination of salicyluric acid urinary excretion, the lower limit of excretion being